Story preview
Continue reading on the publisher site for the full article.
Read on publisher →The Crypto Basic
News Atlas is free and independent. If it’s useful to you, you can support it with a coffee. ☕ Buy me a coffee
Coverage
Tone
Outlets covering it
13
in the last 3 days
First reported
5 days ago
12 outlets since
Countries
12 other outlets reported this story in the last 3 days.
Citi and Stifel raised their AMD price targets for completely different reasons, yet the stock jumped while a chipmaker they both named as a beneficiary sold off. That contradiction is the real story behind today
Citi raised its target price for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceutical company, to £186 from £178 and retained its 'buy' rating...
AMD stock jumps after Citi raises its price target and forecasts a $300B CPU market by 2030.